Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 116 articles:
HTML format
Text format



Single Articles


    July 2017
  1. BOTTERI E, Stoer NC, Sakshaug S, Graff-Iversen S, et al
    Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
    Int J Cancer. 2017 Jul 7. doi: 10.1002/ijc.30878.
    PubMed     Text format     Abstract available


  2. KOU Y, Ji L, Wang H, Wang W, et al
    Connexin 43 Upregulation by Dioscin Inhibits Melanoma Progression via Suppressing Malignancy and Inducing M1 Polarization.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30872.
    PubMed     Text format     Abstract available


    June 2017
  3. GORDON D, Hansson J, Eloranta S, Gordon M, et al
    Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.
    Int J Cancer. 2017 Jun 20. doi: 10.1002/ijc.30843.
    PubMed     Text format     Abstract available


  4. LAURENZANA A, Chilla A, Luciani C, Peppicelli S, et al
    uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30817.
    PubMed     Text format     Abstract available


    May 2017
  5. LI X, Liu H, Amos CI, Lee JE, et al
    A PGC1beta genetic variant associated with nevus count and melanoma mortality.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30802.
    PubMed     Text format    


  6. LIU S, Wang Y, Xue W, Liu H, et al
    Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30785.
    PubMed     Text format     Abstract available


  7. LIN Y, Chahal HS, Wu W, Cho HG, et al
    Association study of genetic variation in DNA repair pathway genes and risk of basal cell carcinoma.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30786.
    PubMed     Text format     Abstract available


  8. JI Y, Chen S, Xiang B, Li K, et al
    Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30775.
    PubMed     Text format     Abstract available


    April 2017
  9. SMITH LD, Leme de Calais F, Raponi M, Mellone M, et al
    Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
    Int J Cancer. 2017;140:1564-1570.
    PubMed     Text format     Abstract available


  10. DOMAGALA P, Hybiak J, Cybulski C, Lubinski J, et al
    BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Int J Cancer. 2017;140:1545-1550.
    PubMed     Text format     Abstract available


    March 2017
  11. TANG JQ, Hou XY, Yang CS, Li YX, et al
    Recent developments in nanomedicine for melanoma treatment.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30708.
    PubMed     Text format     Abstract available


  12. WANG J, Shidfar A, Ivancic D, Ranjan M, et al
    Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
    Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30680.
    PubMed     Text format     Abstract available


  13. VAN DEN BRANDT PA, Schulpen M
    Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
    Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
    PubMed     Text format     Abstract available


  14. SILVERSMIT G, Jegou D, Vaes E, Van Hoof E, et al
    Cure of cancer for seven cancer sites in the Flemish Region.
    Int J Cancer. 2017;140:1102-1110.
    PubMed     Text format     Abstract available


    February 2017
  15. STROTBEK M, Schmid S, Sanchez-Gonzalez I, Boerries M, et al
    miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
    Int J Cancer. 2017 Feb 22. doi: 10.1002/ijc.30661.
    PubMed     Text format     Abstract available


  16. CAINI S, Masala G, Saieva C, Kvaskoff M, et al
    Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2017 Feb 20. doi: 10.1002/ijc.30659.
    PubMed     Text format     Abstract available


  17. LIN X, Chen W, Wei F, Zhou BP, et al
    POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30658.
    PubMed     Text format     Abstract available


  18. TIE Y, Ma X, Zhu C, Mao Y, et al
    Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.
    Int J Cancer. 2017;140:948-958.
    PubMed     Text format     Abstract available


  19. DE VRIES E, Amador JR, Rincon CJ, Uribe C, et al
    Cutaneous Melanoma Attributable to Solar Radiation in Cali, Colombia.
    Int J Cancer. 2017 Feb 10. doi: 10.1002/ijc.30638.
    PubMed     Text format     Abstract available


  20. LIN Y, Chahal HS, Wu W, Cho HG, et al
    Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30634.
    PubMed     Text format     Abstract available


  21. PARK SM, Li T, Wu S, Li WQ, et al
    Niacin intake and risk of skin cancer in US women and men.
    Int J Cancer. 2017 Feb 2. doi: 10.1002/ijc.30630.
    PubMed     Text format     Abstract available


    January 2017
  22. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
    Weight and weight changes in early adulthood and later breast cancer risk.
    Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
    PubMed     Text format     Abstract available


  23. HALONEN PM, Jakobsson MI, Oskari Heikinheimo MA, Riska AE, et al
    Lichen sclerosus and risk of cancer.
    Int J Cancer. 2017 Jan 25. doi: 10.1002/ijc.30621.
    PubMed     Text format     Abstract available


  24. HALPERN N, Sonnenblick A, Uziely B, Divinsky L, et al
    Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30616.
    PubMed     Text format     Abstract available


  25. OUDE OPHUIS CM, Louwman MW, Grunhagen DJ, Verhoef C, et al
    Implementation of the 7th Edition AJCC Staging System: Effects on Staging and Survival for pT1 Melanoma. A Dutch Population Based Study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30607.
    PubMed     Text format     Abstract available


  26. POTRONY M, Rebollo-Morell A, Gimenez-Xavier P, Zimmer L, et al
    IRF4 rs12203592 functional variant and melanoma survival.
    Int J Cancer. 2017 Jan 19. doi: 10.1002/ijc.30605.
    PubMed     Text format     Abstract available


    December 2016
  27. SHEN J, Song R, Wan J, Huff C, et al
    Global methylation of blood leukocyte DNA and risk of melanoma.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30577.
    PubMed     Text format     Abstract available


  28. BENNETT L, Quinn J, McCall P, Mallon EA, et al
    High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30578.
    PubMed     Text format     Abstract available


  29. BAUM C, Weiss C, Gebhardt C, Utikal J, et al
    Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas.
    Int J Cancer. 2016 Dec 9. doi: 10.1002/ijc.30563.
    PubMed     Text format     Abstract available


  30. XU W, Jia G, Cai N, Huang S, et al
    A 16 Yin Yang Gene Expression Ratio Signature for ER+/Node- Breast Cancer.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30556.
    PubMed     Text format     Abstract available


  31. CHEN S, Wang RX, Liu Y, Yang WT, et al
    PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30552.
    PubMed     Text format     Abstract available


  32. LI H, Wang Y, Liu H, Shi Q, et al
    Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival.
    Int J Cancer. 2016 Dec 3. doi: 10.1002/ijc.30545.
    PubMed     Text format     Abstract available


  33. MATEJCIC M, de Batlle J, Ricci C, Biessy C, et al
    Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30536.
    PubMed     Text format     Abstract available


    November 2016
  34. WAKEHAM K, Kavanagh K, Cuschieri K, Millan D, et al
    HPV status and favorable outcome in vulvar squamous cancer.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30523.
    PubMed     Text format     Abstract available


  35. SACCOMANO M, Dullin C, Alves F, Napp J, et al
    Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
    Int J Cancer. 2016;139:2277-89.
    PubMed     Text format     Abstract available


  36. KARASNEH RA, Murray LJ, Cardwell CR
    Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30520.
    PubMed     Text format     Abstract available


  37. VAN LUIJT PA, Heijnsdijk EA, de Koning HJ
    Cost-effectiveness of the Norwegian breast cancer screening program.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30513.
    PubMed     Text format     Abstract available


  38. YANG H, Brand JS, Fang F, Chiesa F, et al
    Time-dependent risk of depression, anxiety and stress-related disorders in patients with invasive and in-situ breast cancer.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30514.
    PubMed     Text format     Abstract available


  39. BODELON C, Oh H, Chatterjee N, Garcia-Closas M, et al
    Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.
    Int J Cancer. 2016 Nov 9. doi: 10.1002/ijc.30512.
    PubMed     Text format     Abstract available


  40. HEGEDUS L, Garay T, Molnar E, Varga K, et al
    The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.
    Int J Cancer. 2016 Nov 4. doi: 10.1002/ijc.30503.
    PubMed     Text format     Abstract available


  41. DESCH A, Gebhardt C, Utikal J, Schneider SW, et al
    D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30498.
    PubMed     Text format     Abstract available


  42. BHUSARI P, Vatsa R, Singh G, Parmar M, et al
    Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500.
    PubMed     Text format     Abstract available


    October 2016
  43. FERRONI P, Santilli F, Cavaliere F, Simeone P, et al
    Oxidant stress as a major determinant of platelet activation in invasive breast cancer.
    Int J Cancer. 2016 Oct 26. doi: 10.1002/ijc.30488.
    PubMed     Text format     Abstract available


    September 2016
  44. DING Z, Xu W, Zhang J, Zou W, et al
    Normalizing GDNF Expression in the Spinal Cord Alleviates Cutaneous Hyperalgesia but not Ongoing Pain in a Rat Model of Bone Cancer Pain.
    Int J Cancer. 2016 Sep 22. doi: 10.1002/ijc.30438.
    PubMed     Text format     Abstract available


  45. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
    PubMed     Text format     Abstract available


  46. VAN DER WAAL D, Ripping TM, Verbeek AL, Broeders MJ, et al
    Breast cancer screening effect across breast density strata: A case-control study.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30430.
    PubMed     Text format     Abstract available


  47. SARRABAYROUSE G, Pich C, Teiti I, Tilkin-Mariame AF, et al
    Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30422.
    PubMed     Text format     Abstract available


  48. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    PubMed     Text format     Abstract available


  49. STRAND F, Humphreys K, Eriksson M, Li J, et al
    Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30427.
    PubMed     Text format     Abstract available


  50. SYNNOTT NC, Murray A, McGowan PM, Kiely M, et al
    Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer?
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30425.
    PubMed     Text format     Abstract available


  51. ROMIEU I, Ferrari P, Chajes V, de Batlle J, et al
    Fiber intake modulates the association of alcohol intake with breast cancer.
    Int J Cancer. 2016 Sep 6. doi: 10.1002/ijc.30415.
    PubMed     Text format     Abstract available


  52. HE W, Lindstrom LS, Hall P, Czene K, et al
    Cause-specific mortality in women with breast cancer in situ.
    Int J Cancer. 2016 Sep 4. doi: 10.1002/ijc.30413.
    PubMed     Text format     Abstract available


    August 2016
  53. ZHANG W, Liu H, Yin J, Wu W, et al
    Genetic Variants in the PIWI-piRNA Pathway Gene DCP1A Predict Melanoma Disease-specific Survival.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30409.
    PubMed     Text format     Abstract available


  54. NOMURA SJ, Dash C, Rosenberg L, Yu J, et al
    Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women's Health Study.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30410.
    PubMed     Text format     Abstract available


  55. ROCKBERG J, Amelio JM, Taylor A, Jorgensen L, et al
    Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence.
    Int J Cancer. 2016 Aug 26. doi: 10.1002/ijc.30407.
    PubMed     Text format     Abstract available


  56. FRY EA, Taneja P, Inoue K
    Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Int J Cancer. 2016 Aug 23. doi: 10.1002/ijc.30399.
    PubMed     Text format     Abstract available


  57. LI WQ, Cho E, Han J, Weinstock MA, et al
    Male pattern baldness and risk of incident skin cancer in a cohort of men.
    Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30395.
    PubMed     Text format     Abstract available


  58. KIISKI JI, Fagerholm R, Tervasmaki A, Pelttari LM, et al
    FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30394.
    PubMed     Text format     Abstract available


  59. KIM HJ, Min A, Im SA, Jang H, et al
    Anti-tumor Activity of the ATR Inhibitor AZD6738 in HER2 positive Breast Cancer Cells.
    Int J Cancer. 2016 Aug 8. doi: 10.1002/ijc.30373.
    PubMed     Text format     Abstract available


  60. LI J, Humphreys K, Eriksson M, Dar H, et al
    Worse quality of life in young and recently-diagnosed breast cancer survivors compared to female survivors of other cancers: A cross-sectional study.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30370.
    PubMed     Text format     Abstract available


    July 2016
  61. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum NSE, MMP-9 and HER2 extra-cellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases?
    Int J Cancer. 2016 Jul 27. doi: 10.1002/ijc.30290.
    PubMed     Text format     Abstract available


  62. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
    Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
    PubMed     Text format     Abstract available


  63. KIM SB, Wildiers H, Krop IE, Smitt M, et al
    Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Int J Cancer. 2016 Jul 18. doi: 10.1002/ijc.30276.
    PubMed     Text format     Abstract available


  64. AYRAULT-PIAULT S, Grosclaude P, Daubisse-Marliac L, Pascal J, et al
    Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).
    Int J Cancer. 2016 Jul 12. doi: 10.1002/ijc.30266.
    PubMed     Text format     Abstract available


  65. MISHRA S, Tewari P, Chaudhari BP, Dwivedi PD, et al
    Deoxynivalenol induced mouse skin tumor initiation: Elucidation of molecular mechanisms in Human Hacat keratinocytes.
    Int J Cancer. 2016 Jul 8. doi: 10.1002/ijc.30260.
    PubMed     Text format     Abstract available


  66. TOMCZAK A, Miller AB, Weichenthal SA, To T, et al
    Long-term exposure to fine particulate matter air pollution and the risk of lung cancer among participants of the Canadian National Breast Screening Study.
    Int J Cancer. 2016 Jul 6. doi: 10.1002/ijc.30255.
    PubMed     Text format     Abstract available


  67. INOUE K, Fry EA
    Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
    Int J Cancer. 2016;139:33-41.
    PubMed     Text format     Abstract available


    June 2016
  68. VAYSSE A, Fang S, Brossard M, Wei Q, et al
    A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.
    Int J Cancer. 2016 Jun 27. doi: 10.1002/ijc.30245.
    PubMed     Text format     Abstract available


  69. MAXWELL R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, et al
    BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Int J Cancer. 2016 Jun 25. doi: 10.1002/ijc.30241.
    PubMed     Text format     Abstract available


  70. GRAUL-CONROY A, Hicks EJ, Fahl WE
    Equivalent chemotherapy efficacy against leukemia in mice treated with topical vasoconstrictors to prevent cancer therapy side effects.
    Int J Cancer. 2016;138:3011-9.
    PubMed     Text format     Abstract available


  71. MIRZAEI H, Naseri G, Rezaee R, Mohammadi M, et al
    Curcumin: A new candidate for melanoma therapy?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30224.
    PubMed     Text format     Abstract available


  72. LIU X, Li J, Qu X, Yan W, et al
    Treatment of kaposiform hemangioendothelioma and tufted angioma.
    Int J Cancer. 2016 Jun 2. doi: 10.1002/ijc.30216.
    PubMed     Text format     Abstract available


  73. GANDINI S, Ferrucci PF, Botteri E, Tosti G, et al
    Prognostic significance of hematological profiles in melanoma patients.
    Int J Cancer. 2016 Jun 2. doi: 10.1002/ijc.30215.
    PubMed     Text format     Abstract available


  74. BRAILLON A, Campergue R
    Screening mammography: There is a golden mammoth in the room!
    Int J Cancer. 2016;138:2762.
    PubMed     Text format    


    May 2016
  75. ORTEGA-MARTINEZ I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, et al
    Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early stage melanoma.
    Int J Cancer. 2016 May 23. doi: 10.1002/ijc.30202.
    PubMed     Text format     Abstract available


  76. HATEM R, Labiod D, Chateau-Joubert S, de Plater L, et al
    Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Int J Cancer. 2016;138:2510-21.
    PubMed     Text format     Abstract available


  77. MANTHRAVADI S, Shrestha A, Madhusudhana S
    Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30185.
    PubMed     Text format     Abstract available


  78. POTRONY M, Carreras E, Aranda F, Zimmer L, et al
    Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30184.
    PubMed     Text format     Abstract available


    April 2016
  79. UBILLOS L, Freire T, Berriel E, Chiribao ML, et al
    Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers.
    Int J Cancer. 2016;138:1719-31.
    PubMed     Text format     Abstract available


    March 2016
  80. SCHRAMA D, Hesbacher S, Angermeyer S, Schlosser A, et al
    Serine 220 phosphorylation of the Merkel cell polyomavirus large T antigen crucially supports growth of Merkel cell carcinoma cells.
    Int J Cancer. 2016;138:1153-62.
    PubMed     Text format     Abstract available


    February 2016
  81. RAIMONDI S, Botteri E, Munzone E, Cipolla C, et al
    Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30062.
    PubMed     Text format     Abstract available


  82. MANIE E, Popova T, Battistella A, Tarabeux J, et al
    Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
    Int J Cancer. 2016;138:891-900.
    PubMed     Text format     Abstract available


  83. VARADAN V, Kamalakaran S, Gilmore H, Banerjee N, et al
    Brief-exposure to preoperative bevacizumab reveals a TGF-beta signature predictive of response in HER2-negative breast cancers.
    Int J Cancer. 2016;138:747-57.
    PubMed     Text format     Abstract available


    January 2016
  84. HARRIS HR, Bergkvist L, Wolk A
    Adherence to the world cancer research fund/american institute for cancer research recommendations and breast cancer risk.
    Int J Cancer. 2016 Jan 25. doi: 10.1002/ijc.30015.
    PubMed     Text format     Abstract available


  85. DARTOIS L, Fagherazzi G, Baglietto L, Boutron-Ruault MC, et al
    Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29987.
    PubMed     Text format     Abstract available


  86. NOMURA SJ, Inoue-Choi M, Lazovich D, Robien K, et al
    WCRF/AICR recommendation adherence and breast cancer incidence among postmenopausal women with and without non-modifiable risk factors.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29994.
    PubMed     Text format     Abstract available


  87. WOODS LM, Rachet B, O'Connell DL, Lawrence G, et al
    Are international differences in breast cancer survival between Australia and England present amongst both screen-detected women and non-screen-detected women? Survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29984.
    PubMed     Text format     Abstract available


  88. WOODS LM, Rachet B, O'Connell D, Lawrence G, et al
    Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): Women diagnosed 1997-2006.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29983.
    PubMed     Text format     Abstract available


  89. CASEY MC, Sweeney KJ, Andrew Lawrence Brown J, Kerin MJ, et al
    Exploring circulating microRNA in the Neoadjuvant Treatment of Breast Cancer.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29985.
    PubMed     Text format     Abstract available


    December 2015
  90. PENG C, Wallwiener M, Rudolph A, Cuk K, et al
    Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29975.
    PubMed     Text format     Abstract available


  91. SISTI JS, Collins LC, Beck AH, Tamimi RM, et al
    Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the Nurses' Health Studies.
    Int J Cancer. 2015 Dec 18. doi: 10.1002/ijc.29968.
    PubMed     Text format     Abstract available


  92. CAI H, Zhang Y, Han TK, Everett RS, et al
    Cation-selective transporters are critical to the ampk-mediated antiproliferative effects of metformin in human breast cancer cells.
    Int J Cancer. 2015 Dec 15. doi: 10.1002/ijc.29965.
    PubMed     Text format     Abstract available


  93. YAO S, Haddad SA, Hu Q, Liu S, et al
    Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER Consortium.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29954.
    PubMed     Text format     Abstract available


  94. NABHOLTZ JM, Chalabi N, Radosevic-Robin N, Dauplat MM, et al
    Multicentric neoadjuvant pilot phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29952.
    PubMed     Text format     Abstract available


  95. OBI N, Heinz J, Seibold P, Vrieling A, et al
    Relationship between menopausal hormone therapy and mortality after breast cancer.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29951.
    PubMed     Text format     Abstract available


  96. FIELD S, Uyttenhove C, Stroobant V, Cheou P, et al
    Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.
    Int J Cancer. 2015 Dec 1. doi: 10.1002/ijc.29946.
    PubMed     Text format     Abstract available


    November 2015
  97. NECHUTA S, Chen WY, Cai H, Poole EM, et al
    A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor positive breast cancer prognosis.
    Int J Cancer. 2015 Nov 25. doi: 10.1002/ijc.29940.
    PubMed     Text format     Abstract available


  98. SALAGAME U, Banks E, Sitas F, Canfell K, et al
    Menopausal Hormone Therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer Lifestyle and EvAluation of Risk (CLEAR) study.
    Int J Cancer. 2015 Nov 24. doi: 10.1002/ijc.29942.
    PubMed     Text format     Abstract available


  99. CAO Y, Hou L, Wang W
    Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A meta-analysis of prospective cohort studies.
    Int J Cancer. 2015 Nov 23. doi: 10.1002/ijc.29938.
    PubMed     Text format     Abstract available


  100. HIRAGA T, Ito S, Nakamura H
    EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation.
    Int J Cancer. 2015 Nov 18. doi: 10.1002/ijc.29921.
    PubMed     Text format     Abstract available


  101. BLEYER A, Baines C, Miller AB
    Impact of Screening Mammography on Breast Cancer Mortality.
    Int J Cancer. 2015 Nov 12. doi: 10.1002/ijc.29925.
    PubMed     Text format     Abstract available


  102. BANERJEE K, Resat H
    Constitutive activation of STAT3 in breast cancer cells: A review.
    Int J Cancer. 2015 Nov 11. doi: 10.1002/ijc.29923.
    PubMed     Text format     Abstract available


  103. RIPPING TM, Hubbard RA, Otten JD, den Heeten GJ, et al
    Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer.
    Int J Cancer. 2015 Nov 4. doi: 10.1002/ijc.29912.
    PubMed     Text format     Abstract available


    October 2015
  104. LIN W, Ren FM, Ren ZF
    The contribution of radiotherapy to subsequent thyroid cancer risk may be confined to a subgroup of breast cancer patients.
    Int J Cancer. 2015 Oct 30. doi: 10.1002/ijc.29907.
    PubMed     Text format    


  105. SUN LM, Lin CL, Liang JA, Kao CH, et al
    Authors' reply to Radiotherapy did not increase thyroid cancer risk among women with breast cancer: A nationwide population-based cohort study.
    Int J Cancer. 2015 Oct 30. doi: 10.1002/ijc.29906.
    PubMed     Text format    


  106. INOUE-CHOI M, Sinha R, Gierach GL, Ward MH, et al
    Red and processed meat, nitrite, and heme iron intakes and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study.
    Int J Cancer. 2015 Oct 27. doi: 10.1002/ijc.29901.
    PubMed     Text format     Abstract available


    September 2015
  107. KOH M, Yong HY, Kim ES, Son H, et al
    A Novel Role for Flotillin-1 in H-Ras-regulated Breast Cancer Aggressiveness.
    Int J Cancer. 2015 Sep 28. doi: 10.1002/ijc.29869.
    PubMed     Text format     Abstract available


  108. HIRKO KA, Chen WY, Willett WC, Rosner BA, et al
    Alcohol consumption and risk of breast cancer by molecular subtype: prospective analysis of the Nurses' Health Study after 26 years of follow-up.
    Int J Cancer. 2015 Sep 18. doi: 10.1002/ijc.29861.
    PubMed     Text format     Abstract available


  109. FANG J, Xiao L, Joo KI, Liu Y, et al
    A Potent Immunotoxin Targeting Fibroblast Activation Protein for Treatment of Breast Cancer in Mice.
    Int J Cancer. 2015 Sep 3. doi: 10.1002/ijc.29831.
    PubMed     Text format     Abstract available


    August 2015
  110. ROMAN M, Sakshaug S, Graff-Iversen S, Vangen S, et al
    Postmenopausal hormone therapy and the risk of breast cancer in Norway.
    Int J Cancer. 2015 Aug 20. doi: 10.1002/ijc.29810.
    PubMed     Text format     Abstract available


  111. PARADA H, Wolff MS, Engel LS, White AJ, et al
    Organochlorine insecticides DDT and chlordane in relation to survival following breast cancer.
    Int J Cancer. 2015 Aug 18. doi: 10.1002/ijc.29806.
    PubMed     Text format     Abstract available


  112. MURILLO R, Diaz S, Perry F, Poveda C, et al
    Increased breast cancer screening and down-staging in Colombian women: A randomized trial of opportunistic breast-screening.
    Int J Cancer. 2015 Aug 11. doi: 10.1002/ijc.29801.
    PubMed     Text format     Abstract available


  113. WANG Y, Xu Y, Chen J, Ouyang T, et al
    TP53 Mutations Are Associated with Higher Rates of Pathologic Complete Response to Anthracycline/Cyclophosphamide-Based Neoadjuvant Chemotherapy in Operable Primary Breast Cancer.
    Int J Cancer. 2015 Aug 3. doi: 10.1002/ijc.29715.
    PubMed     Text format     Abstract available


    July 2015
  114. THORAT MA
    Sentinel lymph node assessment in breast cancer patients receiving neo-adjuvant chemotherapy: to biopsy before or after?
    Int J Cancer. 2015 Jul 30. doi: 10.1002/ijc.29692.
    PubMed     Text format    


  115. REN C, Han C, Fu D, Wang D, et al
    Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.
    Int J Cancer. 2015 Jul 14. doi: 10.1002/ijc.29679.
    PubMed     Text format     Abstract available


    June 2015
  116. MOCELLIN S, Goldin E, Marchet A, Nitti D, et al
    Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis.
    Int J Cancer. 2015 Jun 17. doi: 10.1002/ijc.29644.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: